Newfeed

GERMANTOWN, Md., April 24, 2024 /PRNewswire/ — Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical data from the pivotal Phase 2 study of PRGN-2012 AdenoVers

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: